Combination therapies and integrated peptide programs: which stacks have evidence, which have only program design

Key takeaways

• GLP-1 weight loss plus resistance training plus higher protein is the most evidence-backed combination on the list. A 2026 meta-analysis of 20 RCTs (15,782 participants) found lean mass made up roughly 35.2 percent of weight lost on semaglutide, 25.4 percent on tirzepatide, and 26.8 percent on liraglutide, versus only 17.5 percent when weight loss came from lifestyle plus resistance training. The combination is the protocol that has actual head-to-head numbers on each side .
• GH-axis peptide stacking (CJC-1295 plus ipamorelin) has clinical pharmacology data but no head-to-head outcome trials against recombinant somatropin in eugonadal adults. CJC-1295 binds covalently to serum albumin after injection (the drug affinity complex) and elevates GH and IGF-1 while preserving GH pulsatility, with reported pharmacokinetics supporting an extended multi-day exposure window . Ipamorelin is a selective ghrelin-receptor GH secretagogue with characterized pharmacokinetics . Neither is FDA-approved, neither has a long-term outcome trial against recombinant somatropin, and the Endocrine Society guideline restricts adult GH replacement to confirmed adult GH deficiency .
• Testosterone added to a peptide stack is a separate FDA-regulated decision with its own guideline. The 2018 AUA testosterone deficiency guideline anchors prescribing to a total testosterone threshold of roughly 300 ng/dL on two morning measurements plus symptoms, not to wellness or stack-design preference .
• IV nutrient therapy outside specific deficiency states (true B12 deficiency, documented severe iron deficiency, etc.) does not have a controlled-trial evidence base. A double-blind placebo-controlled fibromyalgia RCT of the Myers cocktail showed no benefit over saline placebo on any outcome at 8 or 16 weeks .
• Drug-drug interaction surface grows as the stack grows. GLP-1 receptor agonists slow gastric emptying enough that the FDA labels and a 2024 endoscopy cohort flag retained gastric contents and altered oral-drug absorption as real concerns . For research and educational purposes only. Not medical advice.

The honest landscape: three buckets, one stack

Integrative clinics in 2026 sell a layered product. The pitch is that a single peptide is a tool, but a coordinated stack (peptide plus hormone optimization plus IV nutrient support plus resistance-training and sleep coaching) is the actual program. The pitch is true in one specific case and is program design in the others. The article sorts the stack into three honest buckets so a reader can tell which layer is supported by controlled trials, which layer has mechanistic plausibility but mostly observational data, and which layer is the clinic's program convention rather than an evidence-based protocol.

Three buckets, in order of how solid the evidence is. Bucket one: controlled-trial-supported combinations (the GLP-1 plus resistance-training plus higher-protein pattern). Bucket two: mechanistic plausibility with observational data (GH-secretagogue peptide stacks layered onto testosterone or HRT in eugonadal adults). Bucket three: program-design conventions (peptide infusion plus IV vitamin therapy plus wellness coaching). All three buckets can sit inside one clinic visit. They are not the same kind of recommendation. For research and educational purposes only. Not medical advice.

Bucket 1: combinations with controlled-trial evidence

GLP-1 weight loss combined with resistance training and higher protein intake is the cleanest example of a peptide-adjacent stack with quantitative head-to-head support. The reason is simple: lean mass losses on GLP-1 receptor agonists are not small, and the comparator (lifestyle plus structured resistance training) has been measured in randomized trials, so the size of the gap is documented rather than inferred. A 2026 systematic review and meta-analysis (Eisa et al., Diabetes, Obesity and Metabolism) pooled 20 randomized controlled trials with 15,782 participants and reported lean mass as a share of total weight lost: 35.2 percent on semaglutide, 25.4 percent on tirzepatide, 26.8 percent on liraglutide, 26.2 percent on lifestyle intervention alone, and 17.5 percent on lifestyle plus resistance training .

The combination interpretation is straightforward. Resistance training plus higher protein intake during GLP-1 weight loss is the only intervention with a randomized comparator that lowers the lean-mass share of total weight loss, and the gap is the largest single delta in the meta-analysis. The pepSmart per-compound article on GLP-1 and muscle loss walks the underlying trial-by-trial detail, and the protein-leucine-and-hypertrophy piece walks the per-meal leucine math separately.

The protocol-level translation that maps onto the resistance-training comparator in the meta-analysis is a higher daily protein target during weight loss (commonly cited in the lean-mass-preservation literature in the range of roughly 1.2 to 1.6 grams per kilogram of reference body weight per day) plus a structured progressive resistance-training cadence of roughly two to three sessions per week. That protein-and-training pattern is what survives the comparator arm independently of the drug.

Bucket 2: mechanistic plausibility with observational data only

GH-axis peptide combinations are the clearest example of bucket two. CJC-1295 and ipamorelin are the headline pair. CJC-1295 is a long-acting GHRH analog with a drug affinity complex that binds covalently to serum albumin after injection, which extends its in vivo exposure window across multiple days relative to native GHRH. A 2006 human study (Ionescu and Frohman, Journal of Clinical Endocrinology and Metabolism) showed CJC-1295 produced about a 7.5-fold elevation in basal GH, a roughly 46 percent rise in mean GH concentration, and a roughly 45 percent rise in IGF-1, while preserving normal GH pulsatility . A 2009 follow-up (Sackmann-Sala et al., Growth Hormone and IGF Research) measured downstream serum protein changes after a single CJC-1295 injection in 11 healthy adult men and identified IGF-1-correlated changes consistent with GH-axis activation .

Ipamorelin is a selective ghrelin-receptor (GHS-R) agonist that drives a clean GH pulse with minimal cortisol or prolactin spillover, and has characterized intranasal and parenteral pharmacokinetics dating to the late 1990s (Johansen et al., Xenobiotica 1998) . Stacked together, CJC-1295 raises tonic GH and ipamorelin layers a pulse on top. The pharmacology is internally consistent. What does not exist in the literature is a long-term randomized head-to-head trial of CJC-1295 plus ipamorelin against recombinant somatropin (the FDA-approved adult GH replacement) on any patient-relevant outcome.

Layering this peptide pair onto eugonadal adults (people with normal HPG-axis function) is even further from a guideline indication. The Endocrine Society's clinical practice guideline on adult GH deficiency (Molitch et al., 2011) restricts GH replacement to confirmed adult GH deficiency, defined by stimulation testing or a proven genetic or structural lesion persistent from childhood . The guideline does not endorse GH-axis stimulation in eugonadal adults for performance, longevity, or wellness indications. CJC-1295 and ipamorelin are not FDA-approved drugs; both are compounded peptides outside the FDA-approved drug quality system, and compounded drugs more generally are not evaluated by FDA for safety, effectiveness, or quality before sale .

Testosterone replacement is a separate decision with its own guideline. The 2018 AUA testosterone deficiency guideline (Mulhall et al., Journal of Urology) anchors prescribing to a total testosterone threshold of about 300 ng/dL measured on two early-morning samples plus consistent symptoms, with baseline hematocrit, PSA, and follow-up monitoring on a defined schedule . The guideline does not endorse testosterone added to a peptide stack as a wellness layer in men who do not meet the diagnostic threshold. Stacking a GH-secretagogue pair on top of off-guideline testosterone, then layering an IV vitamin infusion on top of that, is a clinic-program design decision, not a guideline-driven protocol.

Bucket 3: program-design conventions sold as protocols

IV nutrient therapy is the bucket-three centerpiece of a typical integrative-clinic stack. The pitch in clinics is that an injectable peptide is potentiated by an IV vitamin and electrolyte infusion (Myers cocktail or a variation), and that the bundle is more effective than the peptide alone. The published evidence base for IV vitamin therapy outside specific deficiency states (true B12 deficiency, documented severe iron deficiency, perioperative malnutrition) is thin. A double-blind, placebo-controlled randomized trial of the Myers cocktail in fibromyalgia (Ali et al., Journal of Alternative and Complementary Medicine, 2009) ran a weekly IV intervention against a lactated Ringer placebo for 8 weeks with follow-up at 16 weeks, and reported no statistically significant difference between groups on any outcome .

The honest read is that IV vitamin therapy is a delivery experience and a clinic-program convention, not a documented potentiator for any peptide or weight-loss drug. People often feel better after the infusion. That is a real subjective effect that is consistent with placebo, hydration, or both, and an 8-week placebo-controlled trial is the right design to test the claim. The trial result is what it is.

Wellness coaching, sauna sessions, cold plunges, and red-light exposure rounds the same bucket-three picture. Most have at least observational data that supports a narrow claim (sauna and cardiovascular mortality, for example, has cohort data the pepSmart sauna article walks separately). None of them potentiate a peptide in a documented way. They are pieces of a clinic-program experience layered on top of the peptide, not protocol amplifiers.

Why stack size matters: drug-drug interaction surface

The more layers in a stack, the more the drug-drug and drug-physiology interaction surface grows. The clearest near-term issue is gastric emptying on GLP-1 receptor agonists. The Ozempic prescribing information notes that semaglutide delays gastric emptying and that this may affect the absorption of co-administered oral drugs; clinically meaningful interactions in formal studies were limited at the doses tested, but the label flags the mechanism explicitly . A 2024 JAMA Network Open cross-sectional study (Nasser et al.) measured food retention at endoscopy among GLP-1 RA users versus non-users and reported a measurable increase in retained gastric contents .

The same delayed-emptying signal sits behind the perioperative caution that anesthesiology and gastroenterology societies have voiced for GLP-1 users facing procedural sedation and elective surgery, even though the case-level evidence base is still emerging. The clinical implication for an integrative stack is concrete: oral drugs in the same regimen (thyroid hormone, oral contraceptives, narrow-therapeutic-index drugs) may not absorb on the timing the prescriber assumed, and a stack that adds CJC-1295 plus ipamorelin plus testosterone plus an oral vitamin protocol plus a thyroid replacement and an IV vitamin push during a GLP-1 titration is a stack with multiple absorption assumptions running at once.

FDA has flagged dosing errors with compounded GLP-1 products as a separate patient-harm signal independent of the molecule's safety profile. Compounded preparations differ from the labeled drug in concentration, diluent, and syringe markings, which is where the dosing errors come from . The risk vector compounds (no pun intended) inside an integrative-clinic stack because the prescriber is often layering compounded peptide products, compounded testosterone, and oral supplements at once. Each layer is a separate quality and dosing assumption.

1. Gastric emptying. GLP-1 receptor agonists slow gastric emptying, alter the rate and sometimes the extent of absorption of co-administered oral drugs, and increase the risk of retained gastric contents during procedural sedation. Confirm with the prescribing information of any oral drug added to a GLP-1 titration .
2. Compounded product quality. Compounded peptides, compounded testosterone, and compounded GLP-1 products are not FDA-approved and are not evaluated by FDA for safety, effectiveness, or quality before sale. The dose your tissue receives is the dose the compounder put in the vial, not the dose on the label by definition .
3. Thyroid axis and IGF-1 readings. Layering a GH-secretagogue stack on top of thyroid replacement changes how IGF-1 should be interpreted, because thyroid status and GH-axis activity are linked. A clinic adding CJC-1295 plus ipamorelin to a patient on levothyroxine should be checking thyroid function and IGF-1 on a defined cadence, not just IGF-1.
4. Estradiol and PSA on testosterone. The AUA testosterone deficiency guideline calls for baseline hematocrit, PSA in age-appropriate men, and follow-up testosterone, hematocrit, and PSA monitoring. Stacking testosterone with other axis-active agents does not remove that monitoring need; it adds to it .
5. Cumulative anticoagulation, NSAID, and supplement exposure. IV vitamin pushes commonly include high-dose vitamin C, B-complex, and magnesium. None of those are inert at the doses used in some Myers-cocktail variations. Bleeding risk on concurrent anticoagulants, oxalate load in vitamin C, and magnesium retention in chronic kidney disease are all real considerations that get easier to overlook the larger the stack gets.

Editorial summary

Combination peptide programs are not one thing. The honest read is that one layer of a typical integrative-clinic stack (GLP-1 weight loss plus resistance training plus higher protein) has direct controlled-trial support, with measured numbers on the lean-mass side of the question. Another layer (GH-axis peptide stacks layered onto eugonadal adults, with or without testosterone) has clinical pharmacology and a steady stream of observational data, but does not have head-to-head outcome trials against the FDA-approved alternative and does not match the indications named in the Endocrine Society and AUA guidelines. A third layer (IV nutrient infusions, wellness coaching, recovery modalities) is program-design convention sold as protocol, with at least one negative placebo-controlled RCT on the IV-vitamin centerpiece.

All three layers can sit inside a single clinic visit. They are not the same kind of recommendation, and they should not be sold as if they are. The serious clinical questions that decide whether a multi-layer stack does what its proponents claim are still mostly unfinished: which subgroup of adults sees the largest benefit, which combination of monitoring cadences catches the predictable harms early, and how the drug-drug interaction surface scales as layers are added. None of those questions are settled by mechanistic plausibility.

The pepSmart catalog has the per-compound and per-topic pieces that drill into each layer separately: GLP-1 and muscle loss, protein and leucine and hypertrophy, tesamorelin visceral fat, the peptide-hype-vs-safety read on compounded supply chains, and the peptides-2026 biohacker guide that frames the broader landscape. Read those alongside the brief above if a clinic is selling you the bundled program. For research and educational purposes only. Not medical advice.

Related tools

• Tirzepatide dose calculator - Run tirzepatide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• Body-recomp simulator overview - Public overview of the Pro body-recomposition simulator.